📊 Full opportunity report: The Pharmacy-by-Pharmacy Guide To GLP-1 Prices And Stock on IdeaNavigator AI — validation score, market gap, and execution plan.
Get hardware and tech essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
TL;DR
A product proposal from IdeaNavigator AI outlines a pharmacy-by-pharmacy GLP-1 index that would show patients where specific doses are in stock and at the lowest cash price, while selling the underlying data feed to telehealth firms, employers and PBMs. It responds to a market that has shifted from national shortage to fragmented local availability and wildly varying prices.
A new proposal from IdeaNavigator AI lays out plans for a pharmacy-by-pharmacy GLP-1 index — a free consumer tool that shows patients where specific doses of Ozempic, Wegovy, Zepbound and Mounjaro are in stock and at the lowest cash price, paired with a paid data feed licensed to telehealth prescribers, employer benefits teams and pharmacy benefit managers. The proposal responds to a market that, after the FDA declared GLP-1 shortages resolved, has shifted from a supply crisis to a fragmentation problem: dose-level stockouts persist in some areas, and monthly cash prices for the same drug range from roughly $199 to more than $1,000 depending on the purchase channel.
According to the proposal, the FDA removed GLP-1s from its shortage list — tirzepatide in December 2024 and semaglutide in February 2025 — yet patients continue to encounter localized stockouts of specific doses. At the same time, manufacturers launched competing direct cash-pay channels, including LillyDirect and NovoCare, alongside Costco and Walmart cash programs and the TrumpRx portal introduced in February 2026. The result is a sprawl of prices and dose-level supply gaps that no single source currently normalizes, the proposal states.
The proposed minimum viable product would be a free web tool covering the four brand GLP-1s by drug, dose and ZIP code, seeded with crowdsourced stock reports from patients plus normalized public price data pulled from manufacturer direct sites, Costco and Walmart cash programs, and a GoodRx-style price comparison layer. Dose-level availability alerts would sit on top of the finder. The same normalized dataset would then be exposed as a B2B API and dashboard for one or two design-partner buyers in telehealth or employer benefits.
Revenue, under the plan, would come from licensing the availability and price feed to telehealth prescribers, employers and benefits brokers, and PBMs, with possible referral fees to legitimate pharmacy or manufacturer-direct channels. The proposal specifies no clinical affiliation with any drugmaker. Employers, it notes, report GLP-1s now account for roughly 20% of pharmacy spend, creating demand for cost-steering data.
Why Patients and Employers Need One Index
The proposal targets a gap that affects two very different groups. For patients, the practical question after a GLP-1 prescription is not whether the drug exists but whether their specific dose is available at a nearby pharmacy this week, and what the cheapest legitimate cash option is. With monthly prices swinging from about $199 to over $1,000 depending on channel, the difference between channels can exceed the cost of the drug itself over a year of treatment.
For payers and prescribers, the stakes are financial. If GLP-1s represent roughly one-fifth of pharmacy spend for employers, as the proposal cites, then benefits teams and PBMs lack a normalized, machine-readable view of where drugs are stocked and at what price — the raw material for steering patients toward lower-cost channels. Telehealth prescribers, who increasingly write GLP-1 prescriptions without a physical pharmacy relationship, would use the feed to point patients to pharmacies that actually have the dose in stock, according to the plan.
Top picks for "pharmacy pric stock"
As an affiliate, we earn on qualifying purchases.
From Shortage Crisis to Channel Sprawl
: “The GLP-1 supply picture has changed twice in two years. During 2023 and 2024, high demand for Ozempic, Wegovy, Zepbound and Mounjaro triggered FDA-declared shortages, which temporarily allowed compounding pharmacies to produce cheaper copies of the drugs. The FDA’s shortage resolutions — tirzepatide in December 2024, semaglutide in February 2025 — set enforcement deadlines that pushed compounders out of the market.
What replaced the shortage was fragmentation, the proposal argues. Lilly and Novo Nordisk built their own direct-to-patient cash channels, large retailers launched competing discount programs, and the TrumpRx portal arrived in February 2026. Each channel prices differently, updates availability on its own schedule, and covers different doses — leaving patients to check half a dozen sites manually. The proposed index would aggregate those signals into a single normalized view.
What the Proposal Has Not Yet Proven
The index does not exist yet; it is a build plan, not a launched product. Its core data inputs present open questions. Crowdsourced stock reports can be stale or inaccurate, and the proposal does not specify how reports would be verified or how quickly outdated entries would be removed. Price data scraped or normalized from manufacturer sites and retailer programs may lag when channels change prices.
It is not yet clear whether manufacturer direct channels or large retailers would permit their pricing data to be republished in a third-party index, or whether referral-fee arrangements with pharmacies would raise conflicts of interest. The cited employer spending figure — roughly 20% of pharmacy spend — is presented as an industry report rather than a named study. Whether telehealth firms or benefits teams would pay for a feed they could assemble themselves has not been tested.
The 60-Day Metro Test
The proposal sets a concrete validation path: within 60 days, build a single-metro crowdsourced stock and cash-price tracker for the four brand GLP-1s and run paid landing-page tests aimed at two buyer segments — a consumer page pitched as “find my dose cheapest near me,” and a B2B page offering the normalized availability and price API to telehealth and employer-benefits teams.
The stated success thresholds are at least 200 consumer stock reports submitted in one metro and at least two B2B prospects signing a paid pilot or letter of intent for the feed. If those marks are met, the next phase would extend coverage beyond the pilot metro and formalize the API product for design partners. If not, the plan does not specify a fallback direction. No launch date, founding team, or funding has been announced.
Source: IdeaNavigator AI
Key Questions
Does the GLP-1 pharmacy index exist today?
No. It is a published product proposal from IdeaNavigator AI. The plan calls for a 60-day single-metro pilot before any broader launch.
Why do GLP-1 cash prices vary so much between pharmacies?
According to the proposal, prices depend on the purchase channel — LillyDirect, NovoCare, Costco or Walmart cash programs, retail pharmacies, or the TrumpRx portal — with monthly cash prices ranging from roughly $199 to over $1,000 for the same drug.
Are GLP-1s still in shortage?
The FDA declared the shortages resolved — tirzepatide in December 2024 and semaglutide in February 2025 — but the proposal says patients still encounter localized stockouts of specific doses at individual pharmacies.
How would the index make money if the consumer tool is free?
Revenue would come from licensing the normalized availability and price data feed to telehealth prescribers, employer benefits teams and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels.
How reliable would crowdsourced stock reports be?
That remains unclear. The proposal does not detail verification methods or how quickly stale reports would be removed, which is one of the main open questions about the plan.
Source: IdeaNavigator AI
Evergreen bestsellers Picks
bestsellers
As an affiliate, we earn on qualifying purchases.
